Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin R Kipp

Showing results (171-180 of 189) with videos related to

Pageof 19
Sort By:
Hepatology (Baltimore, Md.)|June 21, 2024
Utility of methylated DNA markers for the diagnosis of malignant biliary stricturesMatthew A Cooley, Amber R Schneider, Emily G Barr Fritcher, et al.
Journal of Surgical Oncology|June 2, 2026
Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage FluidKrystal Mills, Calise K Berger, William R Taylor, et al.
The Journal of Molecular Diagnostics : JMD|February 7, 2021
RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch RepairMargaret A DiGuardo, Jaime I Davila, Rory A Jackson, et al.
Cancer Letters|May 25, 2016
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion proteinYu Wang, Xiwei Ding, Shaoqing Wang, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2024
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patientsSurendra Dasari, Michael R McCarthy, Antonina A Wojcik, et al.
Mayo Clinic Proceedings|February 13, 2026
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency)Michael McCarthy, Antonina A Wojcik, Emily G Barr Fritcher, et al.
Human Pathology|December 25, 2023
Next generation sequencing-based identification of fusion-driven renal neoplasia: A single institution experienceBurak Tekin, Christopher D Hofich, Beth A Pitel, et al.
Human Pathology|May 17, 2025
Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistryRumeal D Whaley, Daniel R Sill, Burak Tekin, et al.
The Journal of Molecular Diagnostics : JMD|February 2, 2025
Clinical Validation of the TruSight Oncology 500 Assay for the Detection and Reporting of Pan-Cancer BiomarkersHussam Al-Kateb, Shannon M Knight, Gopinath Sivasankaran, et al.
The Journal of Allergy and Clinical Immunology|March 12, 2025
A novel dominant-negative variant of IRF8 in a mother and son: Clinical, phenotypic and biological characteristicsHyoungjun Ham, Crescent R Isham, Elizabeth H Ristagno, et al.
Pageof 19

Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|June 21, 2024
Utility of methylated DNA markers for the diagnosis of malignant biliary stricturesMatthew A Cooley, Amber R Schneider, Emily G Barr Fritcher, et al.
Journal of Surgical Oncology|June 2, 2026
Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage FluidKrystal Mills, Calise K Berger, William R Taylor, et al.
The Journal of Molecular Diagnostics : JMD|February 7, 2021
RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch RepairMargaret A DiGuardo, Jaime I Davila, Rory A Jackson, et al.
Cancer Letters|May 25, 2016
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion proteinYu Wang, Xiwei Ding, Shaoqing Wang, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2024
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patientsSurendra Dasari, Michael R McCarthy, Antonina A Wojcik, et al.
Mayo Clinic Proceedings|February 13, 2026
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency)Michael McCarthy, Antonina A Wojcik, Emily G Barr Fritcher, et al.
Human Pathology|December 25, 2023
Next generation sequencing-based identification of fusion-driven renal neoplasia: A single institution experienceBurak Tekin, Christopher D Hofich, Beth A Pitel, et al.
Human Pathology|May 17, 2025
Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistryRumeal D Whaley, Daniel R Sill, Burak Tekin, et al.
The Journal of Molecular Diagnostics : JMD|February 2, 2025
Clinical Validation of the TruSight Oncology 500 Assay for the Detection and Reporting of Pan-Cancer BiomarkersHussam Al-Kateb, Shannon M Knight, Gopinath Sivasankaran, et al.
The Journal of Allergy and Clinical Immunology|March 12, 2025
A novel dominant-negative variant of IRF8 in a mother and son: Clinical, phenotypic and biological characteristicsHyoungjun Ham, Crescent R Isham, Elizabeth H Ristagno, et al.
Pageof 19